摘要
目的探讨血清IL-6和IL-8检测在化疗卵巢癌患者预后评估中的价值。方法采用ELISA方法检测乳腺癌患者40例、卵巢良性疾病患者40例和健康体检者40例血清中IL-6和IL-8水平。结果对照组、卵巢良性疾病组以及卵巢癌组血清IL-6水平分别为(49.96±9.35)ng.L-1、(61.45±10.53)ng.L-1、(161.57±6.87)ng.L-1(P<0.05),血清IL-8水平分别为(53.56±11.59)ng.L-1、(78.58±9.67)ng.L-1、(222.52±11.87)ng.L-1(P<0.05)。卵巢癌患者化疗前血清IL-6、IL-8水平明显高于化疗后(P<0.05)。卵巢癌患者血清IL-6、IL-8水平与分期及预后有关(P<0.05)。结论 lL-6和IL-8可能参与了卵巢癌发生、发展的全过程,其变化可间接反映卵巢癌的生物学行为和预后。
Objective To investigate the value of serum IL-6 and IL-8 detections in evaluation of prognosis of o- varian cancer. Methods ELISA method was used to detect the serum IL-6 and IL-8 levels in the 40 cases of ovari- an cancer, the 40 cases of benign disease of ovary, and the 40 cases of healthy controls. Results The serum levels of IL-6 in the healthy controls,the patients with benign disease of ovary and the patients with ovarian cancer were （49.96±9.35） ng · L-1 ,（61.45 ±10.53） ng· L-1 and （ 161.57 ±6.87） ng· L-1 respectively （P 〈0.05） ; the serum levels of IL-8 were （53.56 ± 11.59 ）ng · L- 1 , （78.58±9.67 ）ng · L- · and （ 222.52 ± 11.87 ）ng · L- · respectively （P 〈 0.05）. The serum levels of IL-6 and IL-8 in the patients with ovarian cancer before chemo- therapy were higher than those after chemotherapy （P 〈 0.05 ）. The serum levels of IL-6 and IL-8 in the patients with ovarian cancer were related with the stage and prognosis （P 〈 0.05）. Conclusion IL-6 and IL-8 may be in- volved in the occurrence and development of ovarian cancer, their changes can reflect the biological behavior and prognosis of ovarian cancer.
出处
《肿瘤基础与临床》
2012年第6期486-488,共3页
journal of basic and clinical oncology
